NCT00724698

Brief Summary

Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,011

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2005

Typical duration for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2005

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2007

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

July 25, 2008

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 29, 2008

Completed
12 months until next milestone

Results Posted

Study results publicly available

July 17, 2009

Completed
Last Updated

February 9, 2022

Status Verified

February 1, 2022

Enrollment Period

2.2 years

First QC Date

July 25, 2008

Results QC Date

May 28, 2009

Last Update Submit

February 7, 2022

Conditions

RhinitisUrticaria

Outcome Measures

Primary Outcomes (1)

  • Adverse Events

    Number of adverse events reported

    Final Visit (Day 15)

Study Arms (1)

Group

Patients diagnosed with Allergic Rhinitis or Chronic Idiopathic Urticaria

Drug: Desloratadine

Interventions

DesloratadineDRUG

Desloratadine 5 mg once daily

Also known as: SCH 034117
Group

Eligibility Criteria

Age12 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Filipino patients diagnosed to have Allergic Rhinitis or Chronic Idiopathic Urticaria

You may qualify if:

  • Outpatient men or women, age 12 years and above.
  • Diagnosis of Allergic Rhinitis or Chronic Idiopathic Urticaria

You may not qualify if:

  • Known hypersensitivity to Desloratadine.
  • Pregnancy or lactation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

RhinitisUrticaria

Interventions

desloratadine

Condition Hierarchy (Ancestors)

Respiratory Tract InfectionsInfectionsNose DiseasesRespiratory Tract DiseasesOtorhinolaryngologic DiseasesSkin Diseases, VascularSkin DiseasesSkin and Connective Tissue DiseasesHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Results Point of Contact

Title
Head, Clinical Trials Registry & Results Disclosure Group
Organization
Schering-Plough
ClinicalTrialsDisclosure@spcorp.com

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 25, 2008

First Posted

July 29, 2008

Study Start

October 1, 2005

Primary Completion

December 1, 2007

Study Completion

December 1, 2007

Last Updated

February 9, 2022

Results First Posted

July 17, 2009

Record last verified: 2022-02